Zalicus Inc. 8-K 2012
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
Date of Report (Date of earliest event reported): May 2, 2012
(Exact name of Registrant as specified in its charter)
245 First Street
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (617) 301-7000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 8.01. Other Events.
On May 2, 2012, Zalicus Inc. ("Zalicus") issued a press release announcing plans to advance its product candidate Z160 into multiple Phase 2a clinical trials for the treatment of pain. The full text of Zalicus's press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Index to Exhibits